Gene Therapy Situation Gets More Awkward With Another Death In Astellas XLMTM Study
Patient Received Lower Dose Of AT132 After Initial Hold Lifted
An expert pointed out that XLMTM patients are already at high risk, but if linked to therapy toxicity, the death could doom the ASPIRO trial.
